Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response.

被引：0
|
作者：
Rifkin, Robert M. [1 ,2 ]
Spitzer, Gary [1 ,3 ]
Greenspan, Andrew [1 ,4 ]
Schwerkoske, John F. [1 ,5 ]
Mandanas, Romeo A. [6 ]
Stephenson, Joe [1 ,3 ]
Kannarkat, George T. [1 ,7 ]
Zhan, Feng [1 ]
Asmar, Lina [1 ]
Beveridge, Roy [1 ,7 ]
机构：
[1] US Oncol Res Inc, Houston, TX USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Carolinas, Greenville, SC USA
[4] Cent Indiana Canc Ctr, Indianapolis, IN USA
[5] Minnesota Oncol Hematol, St Paul, MN USA
[6] Canc Care Associates W, Oklahoma City, OK USA
[7] Fairfax No Virginia Hematol Oncol, Fairfax, VA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：960 / 960
页数：1
相关论文
共 50 条
  • [41] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS A NOVEL CONDITIONING REGIMEN FOR PATIENTS WITH POEMS SYNDROME UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
    Tang, X.
    Shi, X.
    Hu, X.
    Xue, S.
    Qiu, H.
    Han, Y.
    Yan, L.
    Zhou, H.
    Liu, Y.
    Gu, B.
    Sun, A.
    Wu, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S202 - S202
  • [42] Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
    Sunami, Kazutaka
    Shinagawa, Katsuji
    Sawamura, Morio
    Sakai, Akira
    Saburi, Yoshio
    Imamura, Yutaka
    Mizuno, Ishikazu
    Tamaki, Shigehisa
    Kamimura, Tomohiko
    Tsuda, Hiroyuki
    Gondo, Hisashi
    Hino, Norihiko
    Shimazaki, Chihiro
    Miyata, Akira
    Tajima, Fumihito
    Takemoto, Yoshinobu
    Miwa, Akiyoshi
    Chou, Takaaki
    Harada, Mine
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (05) : 635 - 642
  • [43] Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
    Kazutaka Sunami
    Katsuji Shinagawa
    Morio Sawamura
    Akira Sakai
    Yoshio Saburi
    Yutaka Imamura
    Ishikazu Mizuno
    Shigehisa Tamaki
    Tomohiko Kamimura
    Hiroyuki Tsuda
    Hisashi Gondo
    Norihiko Hino
    Chihiro Shimazaki
    Akira Miyata
    Fumihito Tajima
    Yoshinobu Takemoto
    Akiyoshi Miwa
    Takaaki Chou
    Mine Harada
    International Journal of Hematology, 2009, 90 : 635 - 642
  • [44] A Phase 1/2, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan As a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: Result of Phase 1 Trial
    Kim, Jin Seok
    Min, Chang Ki
    Yoon, Sung-Soo
    Lee, Jae Hoon
    BLOOD, 2012, 120 (21)
  • [45] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Kim, Hye Jin
    Yoon, Sung-Soo
    Lee, Dong Soon
    Sohn, Sang Kyun
    Eom, Hyeon Seok
    Lee, Jung Lim
    Chung, Joo Seup
    Kim, Kihyun
    Suh, Cheolwon
    Won, Jong Ho
    Kim, Jin Seok
    Park, Joon Seong
    Kang, Hye Jin
    Seong, Chu Myong
    Kim, Cheol Soo
    Lee, Sang Jae
    Lee, Jae Hoon
    ANNALS OF HEMATOLOGY, 2012, 91 (02) : 249 - 256
  • [46] Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial
    Johansson, Jan-Erik
    Bratel, John
    Hardling, Mats
    Heikki, Lena
    Mellqvist, Ulf-Henrik
    Hasseus, Bengt
    BONE MARROW TRANSPLANTATION, 2019, 54 (09) : 1482 - 1488
  • [47] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Hye Jin Kim
    Sung-Soo Yoon
    Dong Soon Lee
    Sang Kyun Sohn
    Hyeon Seok Eom
    Jung Lim Lee
    Joo Seup Chung
    Kihyun Kim
    Cheolwon Suh
    Jong Ho Won
    Jin Seok Kim
    Joon Seong Park
    Hye Jin Kang
    Chu Myong Seong
    Cheol Soo Kim
    Sang Jae Lee
    Jae Hoon Lee
    Annals of Hematology, 2012, 91 : 249 - 256
  • [48] Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial
    Jan-Erik Johansson
    John Bratel
    Mats Hardling
    Lena Heikki
    Ulf-Henrik Mellqvist
    Bengt Hasséus
    Bone Marrow Transplantation, 2019, 54 : 1482 - 1488
  • [49] High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation
    Demirer, T
    Ayli, M
    Fen, T
    Ozcan, M
    Arat, M
    Buyukberber, S
    Arslan, O
    Gurman, G
    Akan, H
    Ilhan, O
    BONE MARROW TRANSPLANTATION, 2004, 34 (09) : 781 - 786
  • [50] High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma – a retrospective evaluation
    T Demirer
    M Ayli
    T Fen
    M Ozcan
    M Arat
    S Buyukberber
    O Arslan
    G Gurman
    H Akan
    O Ilhan
    Bone Marrow Transplantation, 2004, 34 : 781 - 786
12345